TransThera Biosciences Completes Series D+ Financing Round
China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...
China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly...
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership...
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7...
China-based Jiangsu Hengrui Pharmamceuticals (SHA: 600276) has announced that its enhancer for the zeste homolog...
China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7...